#NASDAQ #San Diego #Canada #Oncolytics Biotech #pelareorep

Oncolytics Biotech® Announces Delisting from the TSX

On August 8, 2025, Oncolytics Biotech® Inc. (Nasdaq: ONCY) announced that it will voluntarily delist its common shares from the Toronto Stock Exchange (TSX), effective August 22, 2025. This strategic move comes as the company, a clinical-stage immunotherapy firm known for developing pelareorep, focuses its resources and efforts on its Nasdaq listing. The decision, made after thorough consideration by the company's board, aims to align with Oncolytics' overarching U.S. business strategy and shareholder base.

Reasons for Delisting from the TSX

The board of Oncolytics Biotech has identified several key factors leading to the decision for voluntary delisting. Notably, the company's shares are already actively traded on the Nasdaq, which has a more significant presence in the U.S. market. The intention is to maintain this primary listing while ceasing to operate as a Foreign Private Issuer, effective January 1, 2026. This shift allows Oncolytics to reassess its domicile, potentially re-domiciling to the U.S. in the future.

One of the primary motivations for the delisting is the associated costs of maintaining a secondary listing on the TSX. The company has concluded that these costs outweigh the benefits given its focus on the U.S. market and its primary shareholder base located in the United States.

Continuity for Shareholders

Despite the delisting from the TSX, Oncolytics assures its Canadian shareholders that they can continue to trade the company's shares on the Nasdaq through brokers that have affiliations with U.S.-registered dealer networks. Furthermore, the company will continue to adhere to regulatory requirements in Canada as a reporting issuer across its provinces and territories, ensuring compliance and transparency.

In accordance with the TSX Company Manual, shareholder approval for the delisting was not necessary since the shares remain listed on the Nasdaq, which is deemed an acceptable alternative market. This smooth transition reflects Oncolytics' commitment to maintaining operational efficiency while staying accountable to its investors.

About Oncolytics Biotech

For those unfamiliar with Oncolytics, it is a clinical-stage biotechnology company dedicated to developing pelareorep, an innovative immunotherapeutic drug administered intravenously. Pelareorep has shown positive clinical outcomes in treating various cancers, notably in first-line pancreatic cancer, metastatic breast cancer, and early-phase studies for anal and colorectal cancers. The drug's mechanism of action is compelling; it transforms